Problem: A 16-year-old patient is started on fluoxetine for moderate major depressive disorder. During a follow-up visit two weeks later, the patient reports feeling more anxious and having trouble sleeping. The patient's mother expresses concern about increased irritability and mentions that the patient has been talking about feeling hopeless more frequently. Question: What should be the nurse practitioner's most appropriate response regarding the FDA warning on SSRIs and suicide risk? Need Online Tutoring?